

NOT A USPTO FORM	Atty. Docket No. X-16542	Serial No 10/579,563
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant L.U. JianLiang	
	International Application Date: November 16, 2004	Group Art Unit 1625
	US Nat'l Entry Date: May 12, 2006	

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
/N.C./	A1	US 6,706,725	March 16, 2004	Bernardon	
/N.C./	AJ	US 2007/0225377	September 27, 2007	Flatt, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BE					
	BF					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
/N.C./	CI	Basak, et al., "Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrheic dermatitis of the scalp," <u>European Academy of Dermatology and Venerology JEADV</u> , Vol. 15, pgs. 77-92 (2001)	
	CJ	Böhm, et al., "Disseminated superficial actinic porokeratosis: Treatment with topical tacalcitol," <u>Journal of the American Academy of Dermatology</u> , Vol. 40, pgs. 479-480 (1999)	
	CK	Cunningham, et al., "Topical calcipotriene for morphea/linear scleroderma," <u>Journal of the American Academy of Dermatology</u> , Vol. 39, pgs. 211-215 (1998)	
	CL	Harrison, "Disseminated superficial actinic porokeratosis responding to calcipotriol," <u>Clinical Exp. Dermatol.</u> , Vol. 19, No. 1, pg. 95 (1994)	
	CM	Lin, et al., "The pleiotropic actions of vitamin D," <u>BioEssays</u> , Vol. 26, pgs. 21-28 (2003)	
/N.C./	CN	Sapadin, et al., "Treatment of Scleroderma," <u>Arch Dermatology</u> , Vol. 138, pgs. 99-105 (2002)	
Examiner Signature	/Nizat Chandrakumar/		Date Considered 10/27/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached. <sup>7</sup> Enter relevant page(s). This form is estimated to take 2-3 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOT A USPTO FORM		Atty. Docket No. X-16542	Serial No 10/579,563
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		First Applicant L.U, JianLiang	
		International Application Date: November 16, 2004	Group Art Unit 1625
		US Nat'l Entry Date: May 12, 2006	
/N.C./	CO	Sato, et al., "Epidermal Growth Factor and 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Suppress Kipogenesis in Hamster Sebaceous Gland Cells <i>In Vitro</i> ," <u>The Society of Investigative Dermatology</u> , Vol. 117, pgs. 965-970 (2001)	
/N.C./	CP	Zinser, et al., "Vitamin D <sub>3</sub> receptor ablation sensitizes skin to chemically induced tumorigenesis," <u>Carcinogenesis</u> , Vol. 23, No. 12, pgs. 2103-2109 (2002)	
	CQ		
	CR		
	CS		
	CT		
	CU		
	CV		
	CW		
	CX		
	CY		
	CZ		

Examiner Signature	/Nizal Chandrakumar/	Date Considered	10/27/2008
-----------------------	----------------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Patent Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached. <sup>8</sup>Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.